- Home
- AAL vs ABVX Comparison
AAL vs ABVX Comparison
Compare AAL & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AAL | ABVX |
|---|---|---|
| Founded | 1930 | 2013 |
| Country | United States | France |
| Employees | 133700 | 67 |
| Industry | Air Freight/Delivery Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.6B | 9.7B |
| IPO Year | 2004 | N/A |
Fundamental Metrics
Financial Performance| Metric | AAL | ABVX |
|---|---|---|
| Price | $10.80 | $124.35 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 13 |
| Target Price | $15.58 | ★ $130.85 |
| AVG Volume (30 Days) | ★ 74.0M | 766.4K |
| Earning Date | 04-23-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $54,633,000,000.00 | N/A |
| Revenue This Year | $10.06 | N/A |
| Revenue Next Year | $5.67 | $0.22 |
| P/E Ratio | $63.53 | ★ N/A |
| Revenue Growth | ★ 0.78 | N/A |
| 52 Week Low | $8.50 | $4.77 |
| 52 Week High | $16.50 | $148.83 |
Technical Indicators
Market Signals| Indicator | AAL | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 33.37 | 55.65 |
| Support Level | $10.76 | $106.37 |
| Resistance Level | $13.77 | $131.27 |
| Average True Range (ATR) | 0.50 | 4.90 |
| MACD | -0.08 | 1.10 |
| Stochastic Oscillator | 17.01 | 87.50 |
Price Performance
Historical ComparisonAbout AAL American Airlines Group Inc.
American Airlines is the world's largest airline by aircraft, capacity, and scheduled revenue passenger miles. Its major US hubs are Dallas/Fort Worth, Charlotte, Chicago, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. It generates over 30% of US airline revenue connecting Latin America with destinations in the United States. After completing a major fleet renewal, the company has the youngest average fleet of US legacy carriers.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.